Related Experiment Video
Updated: Jun 3, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
Clinical pharmacogenetics of methotrexate
Pasqualina Castaldo1, Simona Magi, Annamaria Assunta Nasti
1Department of Neuroscience, Unit of Pharmacology, School of Medicine, University Politecnica delle Marche, Ancona, Italy.
Current Drug Metabolism
|April 8, 2011
Summary
Genetic variations in folate pathways impact methotrexate response and toxicity in patients with cancer and autoimmune diseases. Future pharmacogenetics may personalize methotrexate treatment for better outcomes.
Area of Science:
- Pharmacogenomics
- Molecular Biology
- Clinical Pharmacology
Background:
- Interindividual variability in drug response is influenced by factors like age, gender, diet, and organ function.
- Genetic polymorphisms significantly affect drug efficacy, toxicity, and resistance by altering drug-metabolizing enzymes, transporters, and target molecules.
- Pharmacokinetic and pharmacodynamic parameters are also modulated by genetic variations.
Purpose of the Study:
- To review genetic polymorphisms influencing methotrexate (MTX) response, efficacy, and toxicity.
- To highlight the role of folate pathway gene polymorphisms in MTX treatment outcomes.
- To discuss the potential of MTX pharmacogenetics in tailoring patient treatment.
Main Methods:
- Review of in vitro and clinical evidence on folate pathway gene polymorphisms and MTX response.
- Analysis of studies investigating the impact of genetic variations on MTX efficacy and toxicity.
- Synthesis of current knowledge on MTX pharmacogenetics.
Main Results:
- Common polymorphisms in the folate gene pathway are associated with altered MTX response in patients with malignancy and autoimmune disease.
- These genetic variations can lead to significant MTX toxicity, necessitating intensive monitoring and treatment.
- Evidence suggests a link between specific polymorphisms and variations in MTX efficacy and resistance.
Conclusions:
- Folates pathway genetic polymorphisms significantly influence methotrexate efficacy, resistance, and toxicity.
- While not yet conclusive, MTX pharmacogenetics shows promise for personalized treatment strategies.
- Future clinical practice may leverage pharmacogenetic insights to optimize methotrexate therapy for individual patients.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...